Abstracts tagged "remission and rheumatoid arthritis (RA)"

Abstract Number: 1374 • 2017 ACR/ARHP Annual Meeting
Flares in Patients with Rheumatoid Arthritis Are Strongly Associated with Worse Clinical Outcomes but Are Difficult to Predict
Katie Bechman¹, L. Tweehuysen², James Galloway³, Andrew P. Cope⁴ and Margaret Ma¹, ¹Academic Rheumatology Department, Kings College London, London, United Kingdom, ²Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ³King's College Hospital, Department of Rheumatology, London, London, United Kingdom, ⁴Academic Department of Rheumatology in the Division of Immunology, Infection and Inflammatory Diseases (DIIID), King's College London, London, Great Britain
Background/Purpose: Disease flares in RA are associated with radiographic progression1 and functional deterioration2. Predicting flare is of direct relevance to clinical practice, particularly in patients…
Abstract Number: 1388 • 2017 ACR/ARHP Annual Meeting
Fatigue Is Strongly Associated with the Patient Global Assessment and May Affect Disease Severity and Clinical Remission in Patients with Rheumatoid Arthritis: A Cross-Sectional Study from IORRA, a Large Observational Cohort of Japanese Rheumatoid Arthritis Patients
Naoki Sugimoto¹, Eiichi Tanaka¹, Eisuke Inoue^1,2, Kumiko Saka¹, Eri Sugano¹, Naohiro Sugitani¹, Moeko Ochiai¹, Yoko Shimizu¹, Rei Yamaguchi¹, Katsunori Ikari¹, Ayako Nakajima¹, Atsuo Taniguchi¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Fatigue is a common complaint in patients with rheumatoid arthritis (RA)1. However, its impact on disease activity and clinical remission in patients with RA…
Abstract Number: 1446 • 2017 ACR/ARHP Annual Meeting
Clinical Significance of Serum Levels of ROM (reactive oxygen metabolities) at 12 Weeks during Treatment with Biologic Agents As a Predictor for the 52-Week Remission
Arata Nakajima¹, Masato Sonobe¹, Shinji Taniguchi¹ and Koichi Nakagawa², ¹Orthopaedics, Toho University Sakura Medical Center, Sakura-city, Chiba, Japan, ²Toho University Sakura Medical Center, Sakura-city, Chiba, Japan
Background/Purpose: Oxidative stress induced by reactive oxygen species is thought to be an important mechanism that underlies joint destruction and synovial proliferation. We have shown…
Abstract Number: 1449 • 2017 ACR/ARHP Annual Meeting
Development of a Predictive Score of Successful TNF Inhibitor Tapering in Patients with Rheumatoid Arthritis Remission
Clothilde Barral¹, David Hajage², Bruno Fautrel³, Pierre Lafforgue¹, Florence Tubach² and Thao Pham¹, ¹Rheumatology, APHM, Aix Marseille Univ, Marseille, France, ²APHP, Pitié Salpêtrière Hospital, Département Biostatistics and Public health, Pharmacoepidémiology center (Cephepi), 75018 75013, Paris, France, Paris, France, ³Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France
Background/Purpose: Tapering trials confirmed the feasibility of TNF inhibitors (TNFi) tapering for a relevant proportion of patients in remission and/or low disease activity. However, there…
Abstract Number: 1460 • 2017 ACR/ARHP Annual Meeting
Predictive Factors Associated with Successful Down-Titration of Biologics for Rheumatoid Arthritis Patients in Clinical Practice
Takaaki Komiya¹, Kaoru Minegishi-Takase², Natsuki Sakurai¹, Yuichiro Sato¹, Hideto Nagai³, Naoki Hamada³, Yumiko Sugiyama³, Naomi Tsuchida¹, Yutaro Soejima³, Yosuke Kunishita³, Hiroto Nakano³, Daiga Kishimoto³, Koji Kobayashi², Reikou Kamiyama³, Ryusuke Yoshimi³, Yukiko Asami³, Yohei Kirino³, Shigeru Ohno⁴ and Hideaki Nakajima³, ¹Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ³Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁴Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Randomized clinical trials have shown that if a patient is in sustained remission, biological disease-modifying anti rheumatic drugs (bDMARDs) therapy can be tapered in…
Abstract Number: 1797 • 2017 ACR/ARHP Annual Meeting
Insights from Treating to Target in Rheumatoid Arthritis at an Academic Medical Center
Malithi Jayasundara¹, Ryan Jessee², Jason Weiner³, Tayseer Haroun⁴, Stephanie Giattino⁵, Atul Kapila⁴, Jenelle Hall⁴, Lisa Carnago⁴ and Lisa Criscione-Schreiber⁶, ¹Rheumatology, Duke University, Durham, NC, ²Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC, ³Department of Medicine, Division of Rheumatology and Immunology, Duke University Medical Center, Durham, NC, ⁴Duke University, Durham, NC, ⁵Rheumatology, Duke University Medical Center, Durham, NC, ⁶Internal Medicine, Duke University Medical Center, Durham, NC
Background/Purpose: Current RA guidelines recommend treating to a target of remission or low disease activity (RM/LDA) state. In a prior quality improvement (QI) project, our…
Abstract Number: 2434 • 2017 ACR/ARHP Annual Meeting
Baseline Expressions of Cellular microRNA-31 and microRNA-10a Predict Remission and Low Disease Activity in Patients with Early Rheumatoid Arthritis after Six and Twelve Months of Therapy
Veronika Hruskova^1,2, Klara Prajzlerova³, Martin Komarc⁴, Lucia Vernerova¹, Herman F Mann³, Maria Filkova³, Karel Pavelka³, Jiri Vencovsky³ and Ladislav Senolt³, ¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ²Faculty of Science, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Department of Anthropometrics and Methodology, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: MicroRNAs (miRNAs) post-transcriptionally regulate gene expression by targeting messenger RNAs. The expression of miRNAs was demonstrated to differ between patients with rheumatoid arthritis (RA)…
Abstract Number: 518 • 2016 ACR/ARHP Annual Meeting
Contribution of Patient Global Assessment on Loss and Gain of Disease Remission in Patients with Established Rheumatoid Arthritis in Clinical Practice
George A. Karpouzas¹, Elizabeth Hernandez², Chelsie Cost² and Sarah Ormseth², ¹Harbor UCLA Medical Center, Torrance, CA, ²Rheumatology, Harbor-UCLA Medical Center, Torrance, CA
Background/Purpose: Patient global assessment (PGA) is part of the remission definitions in Rheumatoid arthritis (RA). We explored the proportion of patients who fail to achieve…
Abstract Number: 2587 • 2016 ACR/ARHP Annual Meeting
The Serum Level of Reactive Oxygen Metabolities (ROM) at 12 Weeks during Treatment with Biologic Agents for Rheumatoid Arthritis Is a Predictor for the 52-Week Remission
Arata Nakajima¹, Keiichiro Yamamoto² and Koichi Nakagawa³, ¹Orthopaedics, Toho University Sakura Medical Center, Sakura, Japan, ²Orthopedics, Toho University Sakura Medical Center, Sakura, Japan, ³Toho University Sakura Medical Center, Sakura, Japan
Background/Purpose: Oxidative stress induced by reactive oxygen species is thought to be an important mechanism that underlies joint destruction and synovial proliferation. We have shown…
Abstract Number: 534 • 2016 ACR/ARHP Annual Meeting
Discordance Between Physician-Stated Remission and 28-Joint Disease Activity Score (DAS28)-Defined Remission in Rheumatoid Arthritis Patients
Nan Li¹, Stuart Blackburn², Emma Sullivan², Danuta Kielar¹ and Steve Peterson¹, ¹Janssen Research & Development, LLC, Spring House, PA, ²Adelphi Real World, Manchester, United Kingdom
Background/Purpose: Data were drawn from the 2014 Adelphi RA Disease Specific Programme in 5 European countries (France, Germany, Italy, Spain, UK). Rheumatologists provided details about…
Abstract Number: 2621 • 2016 ACR/ARHP Annual Meeting
Incremental Benefit of Radiographic Inhibition on Long-Term Outcomes in Patients with Rheumatoid Arthritis
Edward C. Keystone¹, Keith A. Betts², Casey A. Schlacher³, Yan Song², Arijit Ganguli³ and Jenny Griffith³, ¹University of Toronto, Toronto, ON, Canada, ²Analysis Group, Inc., Boston, MA, ³AbbVie Inc., North Chicago, IL
Background/Purpose: For the treatment of rheumatoid arthritis (RA) a therapeutic window of opportunity exists– patients treated early have favorable outcomes compared with patients treated after…
Abstract Number: 545 • 2016 ACR/ARHP Annual Meeting
Utility of Power Doppler Ultrasound-Detected Synovitis for the Prediction of Short Term Flare in Rheumatoid Arthritis Patients in Clinical Remission
Facundo Vergara¹, Santiago Ruta¹, Johana Zacariaz¹, Josefina Marin¹, Javier Rosa¹, Ricardo Garcia-Monaco² and Enrique R. Soriano¹, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Radiology and Imagenology Department, Hospital italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Ultrasound has been shown to detect subclinical synovitis in patients who are in clinical remission, in rheumatoid arthritis (RA). The value of power Doppler…
Abstract Number: 2647 • 2016 ACR/ARHP Annual Meeting
Drug Trough Serum Levels Rather Than Antidrug Antibodies Explain Disease Flares in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with TNF Inhibitors in Clinical Remission/Low Disease Activity: A One Year Prospective, Multicenter Study (INMUNOREMAR)
Raimon Sanmarti¹, Jose Inciarte-Mundo¹, Paula Estrada², Maria García Manrique³, Javier Narváez⁴, Antonio Gomez-Centeno³, Jesús Rodríguez-Moreno⁴, Mariona Pascal⁵ and Jordi Yagüe⁵, ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Moisès Broggi-Hospital General de L'Hospitalet - Consorci Sanitari Integral, Sant Joan Despí, Spain, ³Rheumatology Department, Hospital Parc Taulí, Sabadell, Spain, ⁴Rheumatology Department, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain, ⁵Immunology Department, Hospital Clinic de Barcelona, Barcelona, Spain
Background/Purpose: To determine predictive factors of disease flares, including drug trough serum levels and anti-drug antibodies (Ab) in patients with rheumatoid arthritis (RA) or polyarticular…
Abstract Number: 555 • 2016 ACR/ARHP Annual Meeting
HAQ Score Is an Independent Predictor of Sustained Remission in Patients with Rheumatoid Arthritis
Ji-Eun Kim¹, Kyung-Eun Lee², Ji-Hyoun Kang², Yi-Rang Yim¹, Jeong-Won Lee¹, Lihui Wen¹, Dong-Jin Park², Tae-Jong Kim³, Yong-Wook Park² and Shin-Seok Lee³, ¹Chonnam National University Medical School and Hospital, Gwangju, South Korea, ²Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ³Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Korea, The Republic of
Background/Purpose: We compared remission rates, according to different definitions of remission in rheumatoid arthritis (RA) and investigated the potential predictors of sustained remission at the…
Abstract Number: 3085 • 2016 ACR/ARHP Annual Meeting
Do Depression and Anxiety Reduce the Chance of Remission in Rheumatoid Arthritis and Psoriatic Arthritis?
Brigitte Michelsen^1,2, Karen M Fagerli¹, Elisabeth Lie¹, Hilde Berner Hammer³, Glenn Haugeberg^4,5, Eirik K Kristianslund¹ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Martina Hansens Hospital, Bærum, Norway, ⁵Dept. of Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: Depression and anxiety are reported to predict poorer treatment outcomes in rheumatoid arthritis (RA).1 Whether this can be confirmed in larger, prospective studies as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].